High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

13 clinical trials · Condition

Record	Firm	Date
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)	National Cancer Institute (NCI)	2021-05-20
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (NCT05097443)	Shandong Provincial Hospital	2021-04-15
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (NCT05164770)	Shandong Provincial Hospital	2021-03-01
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma (NCT04231877)	University of Washington	2020-10-27
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956)	Mayo Clinic	2020-06-15
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672)	National Cancer Institute (NCI)	2018-12-21
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (NCT01371630)	M.D. Anderson Cancer Center	2011-08-26

Every clearance here is in the API, with alerts when new ones post.